| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
The known metabolites of antipyrine include norantipyrine, 3-hydroxymethylantipyrine, and 4-hydroxyantipyrine. |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Antipyrine is unlikely to harm the infant. Since antipyrine is only available in the United States as ear drops, it is unlikely to be absorbed by the mother and pass into breast milk. No special precautions are required when the mother uses ear drops containing antipyrine. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Breastfeeding and Breast Milk No published information found as of the revision date. |
| References |
|
| Additional Infomation |
Antipyrine is a pyrazolone derivative with the structure 1,2-dihydropyrazol-3-one, where methyl groups are substituted at the N-1 and C-5 positions, and a phenyl group is substituted at the N-2 position. It is a non-narcotic analgesic, antipyretic, nonsteroidal anti-inflammatory drug (NSAID), cyclooxygenase 3 inhibitor, and also an exogenous substance and environmental pollutant. Antipyrine is an analgesic and antipyretic that can be administered orally or as ear drops. It is commonly used to test the effects of other drugs or diseases on hepatic drug-metabolizing enzymes. (Excerpt from Martindale Pharmacopoeia, 30th edition, p. 29) There are reports of the presence of antipyrine in humans, and relevant data exist. Antipyrine is an analgesic and antipyretic that can be administered orally or as ear drops. Antipyrine is commonly used to test the effects of other drugs or diseases on hepatic drug-metabolizing enzymes. (Excerpt from Martindale Pharmacopoeia, 30th Edition, p. 29)
See also: Antipyrine; Benzocaine (component)...View more... Drug IndicationsAntipyrine is an analgesic commonly used to test the effects of other drugs on liver enzymes. When used in combination with benzocaine in an otolytic solution, antipyrine is suitable for relieving symptoms of acute otitis media of various etiologies. Mechanism of ActionAntipyrine primarily acts on the central nervous system, increasing the pain threshold by inhibiting two isoenzymes of cyclooxygenase (COX-1, COX-2, and COX-3), which are involved in the synthesis of prostaglandins (PGs). PharmacodynamicsAntipyrine is an analgesic and antipyretic, administered orally or as ear drops. Antipyrine is commonly used to test the effects of other drugs or diseases on hepatic drug-metabolizing enzymes. (Excerpt from Martindale Pharmacopoeia, 30th Edition, p. 29) |
| Molecular Formula |
C11H12N2O
|
|---|---|
| Molecular Weight |
188.2258
|
| Exact Mass |
188.094
|
| Elemental Analysis |
C, 70.19; H, 6.43; N, 14.88; O, 8.50
|
| CAS # |
60-80-0
|
| Related CAS # |
Antipyrine-d3;65566-62-3
|
| PubChem CID |
2206
|
| Appearance |
White to light yellow crystalline powder.
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
319.0±0.0 °C at 760 mmHg
|
| Melting Point |
109-111 °C(lit.)
|
| Flash Point |
114.8±15.0 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
0.27
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
267
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])=C(C([H])([H])[H])N(C([H])([H])[H])N1C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
VEQOALNAAJBPNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3
|
| Chemical Name |
1,5-dimethyl-2-phenylpyrazol-3-one
|
| Synonyms |
Antipyrine, Phenazone, Azophen, NSC 7945, NSC 7945, NSC 7945, Auralgan
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~531.26 mM)
DMSO : ~100 mg/mL (~531.26 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 110 mg/mL (584.39 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3126 mL | 26.5632 mL | 53.1265 mL | |
| 5 mM | 1.0625 mL | 5.3126 mL | 10.6253 mL | |
| 10 mM | 0.5313 mL | 2.6563 mL | 5.3126 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02037893 | Completed | Drug: Antipyrine and Benzocaine otic solution Drug: Antipyrine Otic Solution Drug: Benzocaine Otic Solution Drug: Placebo Otic solution |
Acute Otitis Media | Currax Pharmaceuticals | 2013-11 | Phase 2 |
| NCT02153541 | Not yet recruiting | Drug: Antipyrine-benzocaine otic solution Other: Glycerin with Oxyquinoline Sulfate |
Asthma | Global United Pharmaceutical Corporation | 2023-04-01 | Phase 2 |
| NCT01584271 | Unknown status | Device: Natural Ear Comfort(TM), a botanical ear drops product | Acute Otitis Externa | Assuta Hospital Systems | 2011-07 | Phase 2 |
| NCT01000519 | Completed | Other: Aerobic Training Other: Progressive resistance training |
Diabetes Mellitus, Type 2 | Singapore General Hospital | 2002-12 | Not Applicable |
| NCT02616458 | Completed | Other: ear pain counseling Other: language power counseling |
Otitis Media | University of Colorado, Denver | 2010-11 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
